vs
Side-by-side financial comparison of First Bancorp, Inc (FNLC) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
Sanara MedTech Inc. is the larger business by last-quarter revenue ($27.5M vs $25.8M, roughly 1.1× First Bancorp, Inc). First Bancorp, Inc runs the higher net margin — 39.4% vs -5.9%, a 45.2% gap on every dollar of revenue. On growth, First Bancorp, Inc posted the faster year-over-year revenue change (17.5% vs 4.6%). First Bancorp, Inc produced more free cash flow last quarter ($34.6M vs $3.9M). Over the past eight quarters, Sanara MedTech Inc.'s revenue compounded faster (21.8% CAGR vs 18.1%).
Patriot Bank, N.A. (PNBK) is the bank holding company for Stamford, Connecticut-based Patriot Bank NA, and is traded on NASDAQ as PNBK.
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
FNLC vs SMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.8M | $27.5M |
| Net Profit | $10.2M | $-1.6M |
| Gross Margin | — | 93.2% |
| Operating Margin | 48.1% | 23.5% |
| Net Margin | 39.4% | -5.9% |
| Revenue YoY | 17.5% | 4.6% |
| Net Profit YoY | 39.7% | 5.3% |
| EPS (diluted) | $0.91 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.8M | $27.5M | ||
| Q3 25 | $24.5M | $26.3M | ||
| Q2 25 | $22.5M | $25.8M | ||
| Q1 25 | $21.8M | $23.4M | ||
| Q4 24 | $22.0M | $26.3M | ||
| Q3 24 | $20.5M | $21.7M | ||
| Q2 24 | $19.2M | $20.2M | ||
| Q1 24 | $18.5M | $18.5M |
| Q4 25 | $10.2M | $-1.6M | ||
| Q3 25 | $9.1M | $-30.4M | ||
| Q2 25 | $8.1M | $-2.0M | ||
| Q1 25 | $7.1M | $-3.5M | ||
| Q4 24 | $7.3M | $-1.7M | ||
| Q3 24 | $7.6M | $-2.9M | ||
| Q2 24 | $6.2M | $-3.5M | ||
| Q1 24 | $6.0M | $-1.8M |
| Q4 25 | — | 93.2% | ||
| Q3 25 | — | 92.9% | ||
| Q2 25 | — | 92.5% | ||
| Q1 25 | — | 92.2% | ||
| Q4 24 | — | 91.4% | ||
| Q3 24 | — | 90.8% | ||
| Q2 24 | — | 90.0% | ||
| Q1 24 | — | 89.8% |
| Q4 25 | 48.1% | 23.5% | ||
| Q3 25 | 45.2% | 11.2% | ||
| Q2 25 | 43.7% | -0.1% | ||
| Q1 25 | 39.3% | -8.9% | ||
| Q4 24 | 39.5% | 18.6% | ||
| Q3 24 | 44.6% | 3.6% | ||
| Q2 24 | 38.8% | -14.3% | ||
| Q1 24 | 39.3% | -8.3% |
| Q4 25 | 39.4% | -5.9% | ||
| Q3 25 | 37.0% | -115.5% | ||
| Q2 25 | 35.8% | -7.8% | ||
| Q1 25 | 32.5% | -15.1% | ||
| Q4 24 | 33.1% | -6.5% | ||
| Q3 24 | 36.9% | -13.2% | ||
| Q2 24 | 32.1% | -17.4% | ||
| Q1 24 | 32.5% | -9.5% |
| Q4 25 | $0.91 | $-0.32 | ||
| Q3 25 | $0.81 | $-3.40 | ||
| Q2 25 | $0.72 | $-0.23 | ||
| Q1 25 | $0.63 | $-0.41 | ||
| Q4 24 | $0.66 | $-0.18 | ||
| Q3 24 | $0.68 | $-0.34 | ||
| Q2 24 | $0.55 | $-0.41 | ||
| Q1 24 | $0.54 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $16.6M |
| Total DebtLower is stronger | $95.5M | $46.0M |
| Stockholders' EquityBook value | $283.1M | $5.9M |
| Total Assets | $3.2B | $72.9M |
| Debt / EquityLower = less leverage | 0.34× | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $16.6M | ||
| Q3 25 | — | $14.9M | ||
| Q2 25 | — | $17.0M | ||
| Q1 25 | — | $20.7M | ||
| Q4 24 | — | $15.9M | ||
| Q3 24 | — | $16.3M | ||
| Q2 24 | — | $6.2M | ||
| Q1 24 | — | $2.8M |
| Q4 25 | $95.5M | $46.0M | ||
| Q3 25 | $95.5M | $45.1M | ||
| Q2 25 | $95.0M | $44.2M | ||
| Q1 25 | $70.0M | $43.4M | ||
| Q4 24 | $95.0M | $30.7M | ||
| Q3 24 | $95.0M | $30.1M | ||
| Q2 24 | $70.0M | $14.4M | ||
| Q1 24 | $70.0M | $9.7M |
| Q4 25 | $283.1M | $5.9M | ||
| Q3 25 | $274.6M | $6.1M | ||
| Q2 25 | $265.5M | $35.4M | ||
| Q1 25 | $259.7M | $36.7M | ||
| Q4 24 | $252.5M | $39.4M | ||
| Q3 24 | $256.8M | $39.8M | ||
| Q2 24 | $244.7M | $41.7M | ||
| Q1 24 | $242.6M | $43.3M |
| Q4 25 | $3.2B | $72.9M | ||
| Q3 25 | $3.2B | $71.1M | ||
| Q2 25 | $3.2B | $98.8M | ||
| Q1 25 | $3.2B | $96.4M | ||
| Q4 24 | $3.2B | $88.1M | ||
| Q3 24 | $3.1B | $88.5M | ||
| Q2 24 | $3.1B | $73.4M | ||
| Q1 24 | $3.0B | $70.9M |
| Q4 25 | 0.34× | 7.74× | ||
| Q3 25 | 0.35× | 7.33× | ||
| Q2 25 | 0.36× | 1.25× | ||
| Q1 25 | 0.27× | 1.18× | ||
| Q4 24 | 0.38× | 0.78× | ||
| Q3 24 | 0.37× | 0.76× | ||
| Q2 24 | 0.29× | 0.34× | ||
| Q1 24 | 0.29× | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $37.8M | $3.9M |
| Free Cash FlowOCF − Capex | $34.6M | $3.9M |
| FCF MarginFCF / Revenue | 133.9% | 14.0% |
| Capex IntensityCapex / Revenue | 12.5% | 0.3% |
| Cash ConversionOCF / Net Profit | 3.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $55.3M | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $37.8M | $3.9M | ||
| Q3 25 | $12.9M | $2.2M | ||
| Q2 25 | $7.4M | $2.7M | ||
| Q1 25 | $2.2M | $-2.0M | ||
| Q4 24 | $26.0M | $932.0K | ||
| Q3 24 | $9.8M | $2.1M | ||
| Q2 24 | $6.4M | $-1.4M | ||
| Q1 24 | $-1.5M | $-1.6M |
| Q4 25 | $34.6M | $3.9M | ||
| Q3 25 | $12.6M | $1.1M | ||
| Q2 25 | $7.2M | $902.7K | ||
| Q1 25 | $828.0K | $-3.7M | ||
| Q4 24 | $24.6M | $859.9K | ||
| Q3 24 | $9.6M | $2.0M | ||
| Q2 24 | $6.3M | $-1.5M | ||
| Q1 24 | $-1.8M | $-1.7M |
| Q4 25 | 133.9% | 14.0% | ||
| Q3 25 | 51.4% | 4.2% | ||
| Q2 25 | 32.1% | 3.5% | ||
| Q1 25 | 3.8% | -15.9% | ||
| Q4 24 | 111.7% | 3.3% | ||
| Q3 24 | 47.0% | 9.4% | ||
| Q2 24 | 32.9% | -7.3% | ||
| Q1 24 | -9.8% | -9.0% |
| Q4 25 | 12.5% | 0.3% | ||
| Q3 25 | 1.2% | 4.0% | ||
| Q2 25 | 0.6% | 6.8% | ||
| Q1 25 | 6.2% | 7.4% | ||
| Q4 24 | 6.7% | 0.3% | ||
| Q3 24 | 0.5% | 0.0% | ||
| Q2 24 | 0.3% | 0.3% | ||
| Q1 24 | 1.8% | 0.4% |
| Q4 25 | 3.72× | — | ||
| Q3 25 | 1.42× | — | ||
| Q2 25 | 0.91× | — | ||
| Q1 25 | 0.31× | — | ||
| Q4 24 | 3.58× | — | ||
| Q3 24 | 1.29× | — | ||
| Q2 24 | 1.03× | — | ||
| Q1 24 | -0.25× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FNLC
Segment breakdown not available.
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
